X4 Pharmaceuticals Expected to Join Russell 3000® Index
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel...
Pharmaceutical
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients Paris, June 13, 2023. Sanofi...
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in...
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision...
Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
Among 100 clinicians, the primary driver of overall oxybate choice, potential to improve patient quality of life, and decrease stress/anxiety...
CEO Addresses Shareholders: Reflect Scientific’s Competitive Position Remains Strong, Showcasing New Milestones and Promising Future
OREM, Utah, June 13, 2023 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (Symbol: RSCF), a leading provider of cutting-edge freezing and...
Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
A sponsored session will feature Dr. Alex Hastie from Bionano, Dr. Suk See De Ravin from National Institute of Health...
Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer
Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board...
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of...
Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer
Duke University School of Law student Cecilia Poston will work alongside Chiesi’s legal team to support her early career development...
SomaLogic Partners with Citogen to Expand Authorized Site Program in Europe
SomaLogic’s 7,000-plex SomaScan® Platform will be used in clinical research, population health studies and nutrigenomics.BOULDER, Colo., June 12, 2023 (GLOBE...
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Webcast scheduled for Thursday, June 15 at 8:30am PTIRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:...
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical...
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H....
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed;...
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and responseSALT LAKE CITY, June 12, 2023...
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel...